Setting A New Client Standard In Study Closeout Timelines

A leading global pharmaceutical company partnered with Medable for a pivotal Phase III diabetes study, aiming to overcome inefficiencies in traditional study delivery and closeout processes. Medable’s innovative approach facilitated a highly accelerated timeline, achieving database lock and a press release in just two weeks.

Key successes included 95% participant data compliance and 85% completion rates. The company’s adoption of Medable's eCOA solution expedited participant recruitment, contributing to a shortened study timeline. Through collaborative technology and process optimization, Medable redefined the study closeout process, enhancing data compliance and fostering confidence in digital solutions. By implementing reusable core processes and technology standards, Medable not only achieved rapid results but also set a new efficiency benchmark for future trials. This partnership exemplified how strategic collaboration, customized digital solutions, and process refinement can accelerate clinical trial timelines and drive faster commercialization of therapies.